-
2024-511169-12-00
5
2023-03-28
Non-Small Cell Lung Cancer
-
2024-515281-14-00
4
2023-02-13
intermediate, high or very high risk MDS in adult patients chronic Mye
-
2024-511330-13-00
4
2023-01-17
Idiopathic Pulmonary Fibrosis
-
2022-500861-29-00
5
2023-01-12
Relapsed or Refractory Multiple Myeloma (RRMM)
-
2024-516147-32-00
9
2022-12-06
Relapsed/refractory multiple myeloma
-
2023-504740-33-00
5
2022-11-22
Fistulizing perianal Crohn's Disease
-
2024-510947-71-00
5
2022-11-21
Chronic Myeloid Leukemia
-
2023-508869-32-00
5
2022-11-10
Cancer - Plasma cell myeloma recurrent
-
2024-516060-28-00
4
2022-10-17
Multiple myeloma patients who received one prior line of therapy conta
-
2023-506927-27-00
5
2022-08-29
Children with short stature either born small for gestational age or w
-
2023-504996-26-00
5
2022-07-21
Metastatic Castration Resistant Prostate Cancer (mCRPC)
-
2023-507634-24-00
5
2022-05-20
Improper function of certain messenger materials in the body that cont
-
2024-512745-16-00
5
2022-04-13
Non–Transfusion-Dependent Alpha- or Beta-Thalassemia
-
2023-506771-10-00
5
2022-03-11
Breast Neoplasm, Neoplasm Metastasis
-
2023-503640-14-00
5
2022-02-17
Newly diagnosed Philadelphia-negative B-cell precursor Acute Lymphobla
-
2023-503826-37-00
5
2022-02-11
Unresectable locally-advanced or metastatic HER2+ breast cancer
-
2024-518304-53-00
5
2022-02-02
Relapsed or Refractory Multiple Myeloma (RRMM)
-
2024-511535-97-00
10
2021-12-16
sickle cell disease (SCD)
-
2023-509133-39-00
5
2021-11-29
Hormone receptor positive, HER2-negative advanced breast cancer
-
2023-506926-35-00
5
2021-09-24
Atherosclerotic cardiovascular disease, chronic kidney disease and sys
-
2023-503772-24-00
10
2021-09-15
IgA Nephropathy
-
2024-516405-23-00
5
2021-06-08
Acute myeloid leukemia (AML) in second or later complete remission (CR
-
2023-504684-16-00
5
2021-06-05
follicular lymphoma (FL) and marginal zone lymphoma (MZL)
-
2023-505615-21-00
5
2021-04-28
Muscle Invasive Bladder Cancer